Dr. Greg van Wyk, CMO and recently appointed CEO, Noxopharm talks about the Company's current milestones and upcoming news related to its lead clinical drug candidate, Veyonda, a chemotherapy and radiation enhancer that is being studied in men with late stage metastatic prostate cancer and that may have broad applicability in other cancer types. Greg notes the explosion of mergers and acquisitions particularly in the oncology space due to increasing interest in combining one or more molecules in treatments.
@Noxopharm
#prostatecancer #cancer #chemotherapy #radiation
Noxopharm
Empowered Patient Podcast